NCT06966700
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 58 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 335 → 338 locations
- Minor Trial sites expanded: 331 → 335 locations
- Publications expanded, about 61 words
- Minor Trial sites expanded: 325 → 331 locations
- Minor Study sites: 325 to 326
- Notable Eligibility criteria expanded, about 20 words
- Secondary endpoints: details revised at 7 of 13 entries
- Site details revised at 19 of 325 sites
- Minor Trial sites expanded: 321 → 325 locationsv53
- Minor Study sites revised (321)v52
- Minor Site contacts updated at 1 of 321 sitesv51
- Minor Study sites: 319 to 321v50
- Minor Study sites revised (319)v49
- Minor Study sites: 318 to 319v48
- Minor Study sites: 317 to 318v47
- Minor Study sites: 315 to 317v46
- Minor Study sites: 314 to 315v45
- Minor Trial sites expanded: 310 → 314 locationsv44
- Minor Trial sites expanded: 307 → 310 locationsv43
- Minor Trial sites expanded: 304 → 307 locations
- Trial sites expanded: 296 → 304 locations
- Minor Study sites: 296 to 304v41
- Minor Study sites: 294 to 296v40
- Minor Study sites: 292 to 294v39
- Minor Study sites: 291 to 292v38
- Minor Trial sites expanded: 287 → 291 locationsv37
- Minor Trial sites expanded: 283 → 287 locationsv36
- Notable Eligibility criteria expanded, about 22 words
- Trial sites expanded: 268 → 283 locations
- Minor Trial sites expanded: 265 → 268 locationsv34
- Minor Trial sites expanded: 254 → 265 locationsv33
- Minor Trial sites expanded: 249 → 254 locationsv32
- Minor Trial sites expanded: 241 → 249 locationsv31
- Minor Study sites: 234 to 241v30
- Minor Study sites: 215 to 234v29
- Minor Study sites: 206 to 215v28
- Minor Study sites: 200 to 206v27
- Minor Study sites: 193 to 200v26
- Minor Study sites: 185 to 193v25
- Minor Study sites: 180 to 185v24
- Minor Study sites: 173 to 180v23
- Minor Study sites: 169 to 173v22
- Minor Study sites: 166 to 169v21
- Minor Study sites: 158 to 166v20
- Minor Study sites: 151 to 158v19
- Minor Study sites: 144 to 151v18
- Minor Study sites: 134 to 144v17
- Minor Study sites: 120 to 134v16
- Minor Study sites: 92 to 120v15
- Minor Study sites: 84 to 92v14
- Minor Study sites: 78 to 84v13
- Minor Study sites: 58 to 78v12
- Minor Study sites: 41 to 58
- Study completion date: Feb 4, 2035 to Dec 29, 2034
- Minor Study sites: 34 to 41v10
- Minor Study sites: 24 to 34v9
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (13)
Show 8 moreShow less
Arms and interventions
Participants receive sacituzumab tirumotecan intravenously (IV) at a dose of 4 mg/kg every 2 weeks (Q2W) + IV pembrolizumab 200 mg every 3 weeks (Q3W), for 12 weeks; then receive IV pembrolizumab 200 mg Q3W and IV carboplatin area under the curve (AUC) 1.5 + IV paclitaxel 80 mg/m\^2 once weekly, for 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant treatment of physician's choice (TPC) may be administered to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); capecitabine 1000-1250 mg/m\^2 oral twice daily on days 1-14 and 22-35 each cycle for 4 six-week cycles; or doxorubicin 60mg/m\^2 (or epirubicin 90 mg/m\^2) IV infusion Q3W/Q2W + cyclophosphamide 600 mg/m\^2 IV infusion Q3W/Q2W for 4 doses.
Participants receive IV carboplatin AUC 1.5 and paclitaxel 80 mg/m\^2 once weekly, alongside pembrolizumab 200 mg Q3W, for 6 weeks; then receive IV pembrolizumab 200 mg Q3W alongside IV cyclophosphamide 600 mg/m\^2 Q3W and either doxorubicin 60 mg/m\^2 Q3W or epirubicin 90 mg/m\^2 Q3W, for up to 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options are olaparib 300 mg oral BID for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); or capecitabine 1000-1250 mg/m\^2 oral BID on days 1-14 and 22-35 each cycle for 4 six-week cycles.
Biologicals: Sacituzumab tirumotecan, Pembrolizumab
Drugs: Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
Sites
338 sites in 41 countries
United States 64, China 30, Japan 22, Canada 16, Italy 12, Brazil 10, Poland 10, Spain 10, United Kingdom 10, Argentina 9, France 9, Turkey (Türkiye) 9, South Korea 8, Peru 7, Colombia 6, Germany 6, Guatemala 6, Belgium 5, Greece 5, Hungary 5, India 5, Malaysia 5, Romania 5, South Africa 5, Taiwan 5, Ukraine 5, Australia 4, Chile 4, Czechia 4, Hong Kong 4, Israel 4, Norway 4, Portugal 4, Sweden 4, Thailand 4, Vietnam 4, Finland 3, New Zealand 2, Philippines 2, Saudi Arabia 1, Singapore 1